Pathophysiological mechanisms underlying the association between low skeletal muscle mass and poor clinical outcomes in older cancer patients including a) systemic inflammation; b) insulin-dependent glucose handling; c) mitochondrial function; d) protein status and e) pharmacokinetics of anticancer drugs (22). This evidence concerns the gene INS and cancer.